VivoPower PLC (VIVO)
| Market Cap | 31.73M -96.5% |
| Revenue (ttm) | 61,000 +281.3% |
| Net Income | -12.79M |
| EPS | -1.92 |
| Shares Out | 16.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 521,943 |
| Open | 1.860 |
| Previous Close | 2.070 |
| Day's Range | 1.690 - 1.945 |
| 52-Week Range | 0.619 - 8.880 |
| Beta | -1.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 22, 2022 |
About VIVO
VivoPower PLC, together with its subsidiaries, provides energy solutions for customized and ruggedized fleet applications, battery and microgrids, and solar and critical power technology and services. It operates through Electric Vehicles, Sustainable Energy Solutions, Solar Development, and Digital Assets segments. The Electric Vehicles segment offers ruggedized battery-powered Electric Vehicle (EV) solutions, including conversion kits for fleet owners in the mining, agriculture, energy utility, defense, police, government, public transport, h... [Read more]
Financial Performance
In fiscal year 2025, VivoPower's revenue was $61,000, an increase of 281.25% compared to the previous year's $16,000. Losses were -$12.79 million, -72.61% less than in 2024.
Financial StatementsNews
VivoPower Announces Effectiveness of New Stock Ticker “VIVO” and Corporate Name Change
LONDON, March 16, 2026 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) ("VivoPower" or the "Company"), a leading B Corp-certified global developer and owner of powered land and data cen...
Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio
CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced that a broad portfolio of its Alethia ...
SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience
CINCINNATI and SEOUL, South Korea , Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, an...
Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger
CINCINNATI , Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has ent...
MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS
CINCINNATI , Nov. 22, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022. Fourth Quarter 20...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TMX, VIVO, RFP, SBTX
NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, EGY, STCN
NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX
NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, ONEM, HNGR
NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...
MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS
CINCINNATI , Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Co...
Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay
CINCINNATI , July 29, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it receive...
MERIDIAN BIOSCIENCE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO
NEW ORLEANS , July 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
MERIDIAN BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Meridian Bioscie...
Meridian Bioscience agrees to $1.5 billion buyout by SD Biosensor, SJL Partners
Meridian Bioscience Inc. VIVO, +7.02% announced an agreement Thursday to be acquired by a consortium of South Korea-based SD Biosensor Inc. 137310, +2.08% and private equity firm SJL Partners LLC in a...
Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction
Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partn...
Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter
CINCINNATI , July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materia...
Meridian Bioscience Is Not Your Average Life Science Company
100% technical buy signals. 8 new highs and up 15.79% in the last month.
Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays
CINCINNATI , June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new s...
Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests
CINCINNATI , May 26, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that its i...
Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference
CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its partic...
Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays
CINCINNATI , May 17, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the contin...
Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History
Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $...
Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2022 Results - Earnings Call Transcript
Meridian Bioscience, Inc. (NASDAQ:VIVO) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President of Investor Relations Jack Kenny - Chief Executiv...
MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS
CINCINNATI , May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (...
Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities
CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that i...